📊 IGC Key Takeaways
Is IGC a Good Investment? Thesis Analysis
IGC Pharma exhibits severe financial distress with minimal revenue ($519K), substantial operating losses ($4.8M), and negative operating cash flow ($3.5M) indicating approximately 3 months of cash runway. The company demonstrates failed or stalled commercialization with no clear path to profitability and critical going concern risk.
Why Buy IGC? Key Strengths
- Conservative capital structure with minimal leverage (Debt/Equity of 0.02x) providing financial flexibility
- Positive stockholders equity of $8.1M providing some balance sheet cushion
- Gross margin of 48.7% indicates reasonable unit economics if commercialization succeeds
IGC Investment Risks to Consider
- Critical liquidity crisis with only $1.1M cash against $3.5M quarterly burn rate signaling imminent insolvency
- Minimal revenue generation against massive operating losses indicates failed product commercialization or pre-revenue status
- Negative operating and free cash flow coupled with low cash reserves suggests bankruptcy risk without immediate capital injection
Key Metrics to Watch
- Monthly cash burn trajectory and total months of operating runway remaining
- Revenue acceleration and achievement of commercial milestones or clinical trial outcomes
- Capital raise announcements, debt restructuring activities, or strategic alternatives including merger or acquisition
IGC Financial Metrics
💡 AI Analyst Insight
IGC Pharma, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IGC Profitability Ratios
IGC vs Healthcare Sector
How IGC Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IGC Overvalued or Undervalued?
Based on fundamental analysis, IGC Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IGC Balance Sheet & Liquidity
IGC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IGC Pharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.22 indicates the company is currently unprofitable.
IGC Growth Metrics (YoY)
IGC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $191.0K | -$1.7M | $-0.02 |
| Q1 2026 | $272.0K | -$1.6M | $-0.02 |
| Q3 2025 | $204.0K | -$1.8M | $-0.02 |
| Q2 2025 | $291.0K | -$1.7M | $-0.02 |
| Q1 2025 | $272.0K | -$2.1M | N/A |
| Q3 2024 | $204.0K | -$2.2M | N/A |
| Q2 2024 | $202.0K | -$2.4M | N/A |
| Q1 2024 | $212.0K | -$2.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IGC Capital Allocation
IGC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IGC Pharma, Inc. (CIK: 0001326205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IGC
What is the AI rating for IGC?
IGC Pharma, Inc. (IGC) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IGC's key strengths?
Claude: Conservative capital structure with minimal leverage (Debt/Equity of 0.02x) providing financial flexibility. Positive stockholders equity of $8.1M providing some balance sheet cushion.
What are the risks of investing in IGC?
Claude: Critical liquidity crisis with only $1.1M cash against $3.5M quarterly burn rate signaling imminent insolvency. Minimal revenue generation against massive operating losses indicates failed product commercialization or pre-revenue status.
What is IGC's revenue and growth?
IGC Pharma, Inc. reported revenue of $519.0K.
Does IGC pay dividends?
IGC Pharma, Inc. does not currently pay dividends.
Where can I find IGC SEC filings?
Official SEC filings for IGC Pharma, Inc. (CIK: 0001326205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IGC's EPS?
IGC Pharma, Inc. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IGC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IGC Pharma, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IGC stock overvalued or undervalued?
Valuation metrics for IGC: ROE of -42.3% (sector avg: 15%), net margin of -659.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IGC stock in 2026?
Our dual AI analysis gives IGC Pharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IGC's free cash flow?
IGC Pharma, Inc.'s operating cash flow is $-3.5M, with capital expenditures of $37.0K. FCF margin is -680.9%.
How does IGC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -659.0% (avg: 12%), ROE -42.3% (avg: 15%), current ratio 1.32 (avg: 2).